Gapping up
In reaction to earnings/guidance:
- VERU +16.9%, MODN +15.5%, LYFT +11.5%, USNA +11.3% (also authorizes $150 mln share repurchase program), MESA +8.9%, TWTR +7.3%, STEP +7.3%, INMD +7.2%, CRTO +7%, MCFT +6.9%, ENPH +6.6%, OI +6.2%, RICK +5.8%, CCK +5.8%, URBN +5.7%, UAA +5.5%, CCJ +5%, GPRE +4.8%, ACGL +4%, BG +3.4%, MAT +3.3%, ARCC +2.7%, YELP +2.6%, TWO +2.5%, IQV +2.3%, EXTR +2%, KO +2%, DCPH +1.9%, RPD +1.7%, THC +1.6%, TEVA +1.4%, BW +1.3% (also announces stock offering), TM +1.3%, CDW +1.3%, PAG +1.1%, BDC +1.1%, QGEN +1%, TMHC +1%
M&A news:
- NEPT +48.7% (acquires controlling interest in Sprout Foods)
- ACIC +40.6% (Archer to list on NYSE through merger with Atlas Crest Investment Corp)
- CMLF +38.3% (agrees to combine with Sema4)
- EGOV +13.7% (Tyler (TYL) will acquire all outstanding shares of NIC in an all-cash transaction valued at ~$2.3 bln)
- FRX +12.9% (Forest Road Acquisition: The Beachbody Company to become a public company through three-way merger with Forest Road Acquisition and Myx Fitness Holdings)
- MTCH +3.6% (to acquire Hyperconnect for $1.725 bln in cash and stock)
- FGNA +2.3% (enters into combination agreement with Opportunity Financial)
Other news:
- GMDA +44.6% (presents Phase 3 data on omidubicel; anticipates BLA submission in 2H21)
- GNFT +31.9% (positive results from the Ph 2 clinical trial evaluating elafibranor)
- PTN +11.3% (files international patent application claiming PL9643)
- ABCL +10.6% (Eli Lilly and AbCellera (ABCL) receive FDA emergency use authorization for COVID-19 for bamlanivimab administered with etesevimab)
- CAN +8.1% (announces improved revenue visibility for 2021; says it should help company achieve profitable growth for the long run)
- KALV +7.6% (stock offering)
- OBSV +4.6% (provides business outlook for 2021; expects NDA submission for Yselty for uterine fibroids in Q2)
- ONCR +4.2% (stock offering)
- FCEL +3.4% (filed a prospectus supplement for the offer and sale of ~964K shares of common stock issuable upon the exercise of the Series C warrants to purchase common stock previously issued)
- VLDR +3.2% (announced a five-year sales agreement to provide Ultra Puck sensors to ThorDrive, an autonomous technology company)
- MREO +3% (pricing of an underwritten public offering of 34,500,000 American Depositary Shares at a public offering price of $2.90 per ADS)
- LADR +2.6% (new CFO)
- PSN +2.2% (wins US Army contract)
- FULT +1.7% (approves $75 mln stock repurchase program)
- KTOS +1.3% (stock offering)
- IVZ +1.3% (reports Jan AUM data)
- LLY +1.3% (Eli Lilly and AbCellera (ABCL) receive FDA emergency use authorization for COVID-19 for bamlanivimab administered with etesevimab)
- SRG +1.2% (new CEO)
- WYNN +1% (WynnBET receives conditional approval for online sports betting in Tennessee)
- BNTX +1% (provides update on vaccine production in Marburg)
Analyst comments:
- DNLI +5.6% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- HAIN +3.9% (upgraded to Overweight from Neutral at Piper Sandler)
- FCX +2.4% (resumed with an Overweight at JP Morgan)
- JWN +2.3% (upgraded to Buy from Hold at Gordon Haskett)
- DCPH +1.9% (upgraded to Outperform from Mkt Perform at SVB Leerink)
- GT +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- BLKB +1.4% (upgraded to Buy from Hold at The Benchmark Company)